HTA-Austria Appraisal Board Team Group, HTA Austria (2026): Tarlatamab (IMDYLLTRA®) for the treatment of extensive-stage small cell lung cancer. Decision Support Document for the Austrian Appraisal Board 0010.
Preview |
PDF
- Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
5MB |
Preview |
PDF (Appendix)
- Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
8MB |
Tarlatamab (IMDYLLTRA®) is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) requiring systemic therapy after disease progression on or after first-line platinum-based chemotherapy. ES-SCLC, which affects around 581 new patients in Austria each year, is an aggressive disease with a poor prognosis and a 5-year survival rate of less than 10%. Tarlatamab is a bispecific T-cell engager that binds simultaneously to tumour cells and T-cells, resulting in T-cell activation and tumour cell death. It is administered as an intravenous infusion until disease progression or unacceptable toxicity. Tarlatamab has orphan designation and received marketing authorisation from the European Commission in May 2026.
The clinical evidence is based on the Joint Clinical Assessment (JCA) conducted under the EU-Regulation 2021/2282 and comprises the randomised controlled phase III trial, DeLLphi-304, as well as indirect treatment comparisons (ITCs). Compared with topotecan, tarlatamab significantly prolonged median overall survival in all three populations assessed: in platinum-resistant patients (11.1 vs. 5.8 months; HR 0.49; 95% CI 0.33–0.73), in patients with a recurrence-free interval ≤6 months (11.2 vs. 6.4 months; HR 0.58; 95% CI 0.43–0.79) and in platinum-sensitive patients (13.9 vs. 11.4 months; HR 0.63; 95% CI 0.42–0.95). Results for progression-free survival, response rate, patient-reported outcomes and quality of life were heterogeneous and limited by the open-label design. Tarlatamab was associated with fewer severe adverse events but showed a characteristic toxicity profile including cytokine release syndrome (approx. 50–60%) and immune effector cell-associated neurotoxicity syndrome (7.1%), which clinical experts considered mostly early-onset, low-grade and manageable. The ITCs versus CAV, carboplatin plus etoposide and platinum rechallenge showed very low certainty of evidence and did not allow reliable conclusions.
No pharmacoeconomic model was submitted for Austria at data cut-off. Four published cost-utility analyses from Canada, the United Kingdom, the United States and China consistently concluded that tarlatamab is not cost-effective under the respective assumptions. To achieve cost-effectiveness, price reductions of approximately 56–95% would be required, depending on the analysis. In addition, a substantial budget impact is to be expected. Organisational recommendations include inpatient monitoring after the first doses and staff training. The role of tarlatamab will depend on whether the survival benefit is confirmed in routine practice, as the transferability of the trial population to routine care is limited.
| Item Type: | DSD: Appraisal Board |
|---|---|
| Keywords: | Tarlatamab, small cell lung cancer (extensive-stage), bispecific T-cell engager (BiTE), DLL3 (delta-like ligand 3), immunotherapy |
| Subjects: | QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts W Health professions > W 74-80 Medical economics. Health care costs WB Practice of medicine > WB 300-962 Therapeutics WF Respiratory system |
| Language: | English |
| Series Name: | Decision Support Document for the Austrian Appraisal Board 0010 |
| Deposited on: | 19 Nov 2026 11:09 |
| Last Modified: | 19 Nov 2026 12:12 |
Repository Staff Only: item control page